A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies. Shi, J., Zheng, J., Zhang, X., Tai, W., Compas, R., Deno, J., Jachym, N., Verma, A., Wang, G., Guan, X., Odle, A., Wan, Y., Li, F., Perlman, S., Qiao, L., Du, L.  JCI Insight. 


(9) Lys417 acts as a molecular switch that regulates the conformation of SARS-CoV-2 spike protein. Geng, Q., Wan, Y., Hsueh, F., Shang, J., Ye, G., Bu, F., Herbst, M., Wilkens, R., Liu, B., Li, F. eLife.  

(7) Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19. Ye G, Pan, R., Bu, F., Zheng, J., Mendoza, A., Wen, W., Du, L., Spiller, B., Wadzinski, B.E., Liu, B., Perlman, S., Li, F. J Virol. 

(6) Glycoproteomic landscape and structural dynamics of TIM family immune checkpoints enabled by mucinase SmE. Chongsaritsinsuk, J., Steigmeyer, A.D., Mahoney, K.E. et al. Nat Communications. 

(5) DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors. Jimmidi, R., Chamakuri, S., Lu, S. et al. Communications Chemistry. 

(4) SARS-CoV-2 evolved variants optimize binding to cellular glycocalyx, Kim, S. H., et al., Cell Reports Physical Science. 

(3) Rapid resistance profiling of SARS-CoV-2 protease inhibitorsMoghadasi, S.A. et al., bioRxiv: the preprint server for biology. 

(2) Flavivirus nonstructural proteins and replication complexes as antiviral drug targets, Elsen, K., Chew, B., Ho, J., Luo, D. Current Opinion in Virology

(1)  SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376, Heilmann, E. et al., Science translational medicine. 


(11) Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors, Moghadasi, S.A. et al., Science Advances. 

(10) Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines, Murphy, H., & Ly, H., Vaccines. 

(9) SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral 3'-Deoxy-3', 4'-dihydro-cytidine Nucleotide from RNA. Moeller, N. H., Passow, K. T., Harki, D. A., & Aihara, H., Viruses. 

(8) Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants, Yang, Y., & Du, L., Cellular & molecular immunology.  

(7) Spike-heparan sulfate interactions in SARS-CoV-2 infection, Kearns, F. L., et al., Current opinion in structural biology. 

(6) Structural basis for mouse receptor recognition by SARS-CoV-2 omicron variant, Zhang, W. et al., Proceedings of the National Academy of Sciences

(5) SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral 3'-Deoxy-3',4'-didehydro-cytidine Nucleotide from RNA, Moeller, N.H. et al., Viruses 

(4) Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro/3CLpro in Living Cells, Moghadasi, S.A. et al., mBio

(3) Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1, Geng, Q. et al., Journal of Virology

(2) Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN, Moeller, N.H. et al., Proceedings of the National Academy of Sciences

(1) Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain, Ye, G. et al., Nature Communications


(4) Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection, Geng, Q. et al., PLOS Pathogens

(3) The Development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates, Ye, G. et al., eLife

(2) Seroprevalence of SARS-CoV-2 (COVID-19) exposure in pet cats and dogs in Minnesota, USA, Dileepan, M. et al., Virulence

(1) Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium, Fiege, J. et al., PLOS Pathogens


(5) Cell entry mechanisms of SARS-CoV-2, Shang, J. et al., Proceedings of the National Academy of Sciences

(4) Structural basis of receptor recognition by SARS-CoV-2, Shang, J. et al., Nature

(3) Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry, Shang, J. et al., PLOS Pathogens

(2) Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry, Wan, Y., et al., Journal of Virology

(1) Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-Long structural studies of SARS coronavirus, Wan et al., Journal of Virology